Zevra Therapeutics, Inc. (ZVRA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth No data.
33/64
2.6 / 5 stars
All 64 Win/Lose results and 56 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 4 losses, 2 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinZVRA / S&P 53.86% / 15.20% |
WinZVRA / S&P 119.40% / 15.00% |
LoseZVRA / S&P -500.00% / 50.40% |
| 2026-Q12/3 |
WinZVRA / S&P 4.02% / -4.33% |
WinZVRA / S&P 201.29% / 11.30% |
LoseZVRA / S&P -203.65% / 27.70% |
| 2025-Q41/2 |
LoseZVRA / S&P -5.78% / 2.65% |
WinZVRA / S&P 350.91% / 9.00% |
No dataZVRA / S&P / 13.40% |
| 2025-Q31/2 |
LoseZVRA / S&P 7.95% / 8.12% |
WinZVRA / S&P 244.60% / 4.61% |
No dataZVRA / S&P / 13.45% |
| 2025-Q22/2 |
WinZVRA / S&P 17.62% / 10.94% |
WinZVRA / S&P 161.81% / 4.83% |
No dataZVRA / S&P / 10.63% |
| 2025-Q11/2 |
LoseZVRA / S&P -10.19% / -4.27% |
WinZVRA / S&P 46.47% / 4.98% |
No dataZVRA / S&P / 10.57% |
| 2024-Q41/2 |
WinZVRA / S&P 20.17% / 2.41% |
LoseZVRA / S&P -14.02% / 5.25% |
No dataZVRA / S&P / 6.15% |
| 2024-Q32/2 |
WinZVRA / S&P 41.63% / 5.89% |
WinZVRA / S&P 47.85% / 5.89% |
No dataZVRA / S&P / 6.11% |
| 2024-Q21/2 |
LoseZVRA / S&P -15.52% / 4.28% |
WinZVRA / S&P 43.21% / 5.38% |
No dataZVRA / S&P / 5.12% |
| 2024-Q11/2 |
LoseZVRA / S&P -11.45% / 10.56% |
WinZVRA / S&P 195.67% / 5.71% |
No dataZVRA / S&P / 5.59% |
| 2023-Q42/2 |
WinZVRA / S&P 35.89% / 11.69% |
WinZVRA / S&P 170.26% / 6.81% |
No dataZVRA / S&P / 7.78% |
| 2023-Q31/2 |
LoseZVRA / S&P -5.49% / -3.27% |
WinZVRA / S&P 54.49% / 7.52% |
No dataZVRA / S&P / -5.03% |
| 2023-Q21/2 |
LoseZVRA / S&P -7.27% / 8.74% |
WinZVRA / S&P 68.59% / 9.50% |
No dataZVRA / S&P / -8.57% |
| 2023-Q11/2 |
WinZVRA / S&P 19.83% / 7.50% |
LoseZVRA / S&P -54.28% / 10.77% |
No dataZVRA / S&P / -15.69% |
| 2022-Q40/2 |
LoseZVRA / S&P -26.44% / 7.56% |
LoseZVRA / S&P -64.53% / 11.88% |
No dataZVRA / S&P / -17.99% |
| 2022-Q31/2 |
WinZVRA / S&P 39.91% / -4.88% |
LoseZVRA / S&P -62.30% / 13.47% |
No dataZVRA / S&P / -1.41% |
| 2022-Q21/2 |
WinZVRA / S&P -11.33% / -16.10% |
LoseZVRA / S&P -65.44% / 13.71% |
No dataZVRA / S&P / 11.04% |
| 2022-Q10/2 |
LoseZVRA / S&P -42.25% / -4.60% |
LoseZVRA / S&P -12.09% / 15.97% |
No dataZVRA / S&P / 42.23% |
| 2021-Q41/3 |
LoseZVRA / S&P -6.65% / 11.03% |
WinZVRA / S&P 115.61% / 15.00% |
LoseZVRA / S&P -17.61% / 96.40% |
| 2021-Q31/2 |
LoseZVRA / S&P -27.22% / 0.58% |
WinZVRA / S&P 131.21% / 10.77% |
No dataZVRA / S&P / 69.42% |
| 2021-Q22/2 |
WinZVRA / S&P 39.35% / 8.55% |
WinZVRA / S&P 30.03% / 6.58% |
No dataZVRA / S&P / 51.81% |
| 2021-Q10/1 |
LoseZVRA / S&P -17.86% / 6.17% |
No dataZVRA / S&P / -1.06% |
No dataZVRA / S&P / 7.39% |
| 2020-Q41/1 |
WinZVRA / S&P 23.89% / 12.15% |
No dataZVRA / S&P / -3.72% |
No dataZVRA / S&P / -33.42% |
| 2020-Q31/1 |
WinZVRA / S&P 96.86% / 8.93% |
No dataZVRA / S&P / -2.04% |
No dataZVRA / S&P / -27.10% |
| 2020-Q21/1 |
WinZVRA / S&P 27.56% / 20.54% |
No dataZVRA / S&P / -0.46% |
No dataZVRA / S&P / -27.11% |
| 2020-Q10/1 |
LoseZVRA / S&P -40.63% / -19.60% |
No dataZVRA / S&P / 3.47% |
No dataZVRA / S&P / -14.75% |
| 2019-Q40/1 |
LoseZVRA / S&P -44.99% / 9.07% |
No dataZVRA / S&P / 5.36% |
No dataZVRA / S&P / 2.99% |
| 2019-Q30/1 |
LoseZVRA / S&P -60.63% / 1.70% |
No dataZVRA / S&P / 5.02% |
No dataZVRA / S&P / 0.21% |
| 2019-Q21/1 |
WinZVRA / S&P 4.79% / 4.30% |
No dataZVRA / S&P / 6.64% |
No dataZVRA / S&P / 8.65% |
| 2019-Q10/1 |
LoseZVRA / S&P -6.18% / 13.65% |
No dataZVRA / S&P / 8.12% |
No dataZVRA / S&P / 14.29% |
| 2018-Q40/1 |
LoseZVRA / S&P -62.92% / -13.52% |
No dataZVRA / S&P / 9.05% |
No dataZVRA / S&P / 18.23% |
| 2018-Q30/1 |
LoseZVRA / S&P -26.15% / 7.71% |
No dataZVRA / S&P / 10.21% |
No dataZVRA / S&P / 19.06% |
| 2018-Q20/1 |
LoseZVRA / S&P -17.72% / 3.43% |
No dataZVRA / S&P / 9.03% |
No dataZVRA / S&P / 14.46% |
| 2018-Q11/1 |
WinZVRA / S&P 95.06% / -0.76% |
No dataZVRA / S&P / 7.68% |
No dataZVRA / S&P / 12.46% |
| 2017-Q41/1 |
WinZVRA / S&P 9.46% / 6.64% |
No dataZVRA / S&P / 7.03% |
No dataZVRA / S&P / 13.82% |
| 2017-Q30/1 |
LoseZVRA / S&P -7.50% / 4.48% |
No dataZVRA / S&P / 5.68% |
No dataZVRA / S&P / 17.57% |
| 2017-Q20/1 |
LoseZVRA / S&P -18.37% / 3.09% |
No dataZVRA / S&P / 4.83% |
No dataZVRA / S&P / 17.74% |
| 2017-Q11/1 |
WinZVRA / S&P 66.10% / 6.07% |
No dataZVRA / S&P / 3.67% |
No dataZVRA / S&P / 13.32% |
| 2016-Q40/1 |
LoseZVRA / S&P -34.30% / 3.82% |
No dataZVRA / S&P / 2.09% |
No dataZVRA / S&P / 7.05% |
| 2016-Q31/1 |
WinZVRA / S&P 12.81% / 3.85% |
No dataZVRA / S&P / 0.20% |
No dataZVRA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ZVRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 30.65% | 20.78% |
| Annualized return | 30.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ZVRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 30.22% | 83.14% |
| Annualized return | 5.42% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ZVRA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -83.32% | 319.30% |
| Annualized return | -16.40% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |